5α还原酶抑制剂在前列腺癌治疗中的作用

庞然; 卢建新

doi:10.13201/j.issn.1001-1420.2014.04.028

5α还原酶抑制剂在前列腺癌治疗中的作用

庞然,
卢建新^,

- 中国中医科学院广安门医院泌尿外科(北京, 100053)

详细信息

通讯作者: 卢建新, E-mail:13501392760@163.com

中图分类号: R737.25

收稿日期: 2013-06-25

Utilization of 5-α reductase inhibitor in treating prostate cancer

PANG Ran,
LU Jian-xin^,

- Department of Urology, Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053

More Information

Corresponding author: LU Jian-xin, E-mail: 13501392760@163.com

Received Date: 25 June 2013

摘要

摘要: 前列腺癌(PCa)是男性泌尿生殖系统最常见的恶性肿瘤之一。5α还原酶抑制剂可以抑制睾酮向双氢睾酮转化,阻断双氢睾酮的生物学效应,可以在PCa的化学预防与治疗中起到一定作用。其化学预防作用已经在两项大型临床试验中得到验证,而其治疗作用也随着大型临床试验REDEEM研究结果的公布引起了广泛的关注,本文对5α还原酶抑制剂对PCa的治疗进展做一综述。
- 前列腺癌 /
- 5α还原酶抑制剂 /
- 治疗
Abstract: Prostate cancer is one of the most common urogenital malignant tumors in male.The conversion from testosterone to dihydrotestosterone can be suppressed by 5-α reductase inhibitor.Thus, the biological effects of dihydrotestosterone on human body can be blocked.It is found that 5-α reductase inhibitor can be used in chemoprevention and treatment of prostate cancer.Its effects on chemoprevention of prostate cancer have been confirmed by two famous clinical trials.Furthermore, great attention has been paid to the curative effects of 5-α reductase inhibitor due to the announcement of outcomes in REDEEM study.In this paper, we review the utilization of 5-α reductase inhibitor in treating prostate cancer.
- prostate cancer /
- 5-α reductase inhibitor /
- treatment

HTML全文

参考文献(28)

[1]	Siegel R, Ward E, Brawley O, et al.Cancer statistics, 2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J].CA Cancer J Clin, 2011, 61 (4):212-236.
[2]	那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].2011版.北京:人民卫生出版社, 2011:63-64.
[3]	Dehm S M, Tindall D J.Molecular regulation of androgen action in prostate cancer[J].J Cell Biochem, 2006, 99 (2):333-344.
[4]	Uemura M, Tamura K, Chung S, et al.Novel 5alphasteroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer[J].Cancer Sci, 2008, 99 (1):81-86.
[5]	Thomas L N, Douglas R C, Lazier C B, et al.Levels
[6]	of 5alpha-reductase type 1and type 2are increased in localized high grade compared to low grade prostate cancer[J].J Urol, 2008, 179 (1):147-151.
[6]	Cayatte C, Pons C, Guigonis J M, et al.Protein profiling of rat ventral prostate following chronic finasteride administration:identification and localization of a novel putative androgen-regulated protein[J].Mol Cell Proteomics, 2006, 5 (11):2031-2043.
[7]	Xu Y, Dalrymple S L, Becker R E, et al.Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers[J].Clin Cancer Res, 2006, 12 (13):4072-4079.
[8]	Schmidt L J, Regan K M, Anderson S K, et al.Effects of the 5alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts[J].Prostate, 2009, 69 (16):1730-1743.
[9]	Bass R, Perry B, Langenstroer P, et al.Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells[J].J Urol, 2009,
[181]	(2):615-619;discussion 619-620.
[10]	Mostaghel E A, Geng L, Holcomb I, et al.Variability in the androgen response of prostate epithelium to
[5]	alpha-reductase inhibition:implications for prostate cancer chemoprevention[J].Cancer Res, 2010, 70 (4):1286-1295.
[11]	Fleshner N E, Lucia M S, Egerdie B, et al.Dutasteride in localised prostate cancer management:the REDEEM randomised, double-blind, placebo-controlled trial[J].Lancet, 2012, 379 (9821):1103-1111.
[12]	Tombal B, Lecouvet F.Words of wisdom:Re:Dutasteride in localised prostate cancer management:the REDEEM randomised, double-blind, placebo-controlled trial[J].Eur Urol, 2012, 61 (6):1265-1266.
[13]	Walsh P C.Re:Dutasteride in localised prostate cancer management:the REDEEM randomised, double-blind, placebo-controlled trial[J].J Urol, 2012, 188 (1):110-111.
[14]	Fleshner N E.REDEEM trial investigators.Dutasteride and active surveillance of low-risk prostate cancer[J].Lancet, 2012, 379 (9826):1590.
[15]	Chung H T, Noworolski S M, Kurhanewicz J, et al.A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer[J].BJU Int, 2011, 108 (8 Pt 2):E164-E170.
[16]	Perrotti M, Jain R, Abriel L M, et al.Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate:a pilot study[J].Urol Oncol, 2012, 30 (2):133-138.
[17]	Bañez L L, Blake G W, McLeod D G, et al.Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer:a comparative analysis of two phase II trials with a longterm follow-up[J].BJU Int, 2009, 104 (3):310-314.
[18]	Monk J P, Halabi S, Picus J, et al.Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy:resultsof Cancer and Leukemia Group B (CALGB) 9782[J].Cancer, 2012, 118 (17):4139-4147.
[19]	Schr der F H, Bangma C H, Wolff J M, et al.Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy?Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study[J].BJU Int, 2009, 103 (5):590-596.
[20]	Stanbrough M, Bubley G J, Ross K, et al.Increased expression of genes converting adrenal androgens to testosterone in androgen independent prostate cancer[J].Cancer Res, 2006, 66 (5):2815-2825.
[21]	Locke J A, Guns E S, Lubik A A, et al.Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer[J].Cancer Res, 2008, 68 (15):6407-6415.
[22]	Shah S K, Trump D L, Sartor O, et al.Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy[J].J Urol, 2009, 181 (2):621-626.
[23]	Taplin M E, Regan M M, Ko Y J, et al.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer[J].Clin Cancer Res, 2009, 15 (22):7099-7105.
[24]	Sartor O, Nakabayashi M, Taplin M E, et al.Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone[J].Clin Genitourin Cancer, 2009, 7 (3):E90-E92.
[25]	Sartor O, Gomella L G, Gagnier P, et al.Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer:the Therapy Assessed by Rising PSA (TARP) study rationale and design[J].Can J Urol, 2009, 16 (5):4806-4812.